Tags

Type your tag names separated by a space and hit enter

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Abstract

BACKGROUND

Clinical guidelines for cervical cancer screening have incorporated comparative risks of cervical intraepithelial neoplasia grade 3 or cancer (CIN3(+)) for various screening outcomes to determine management. Few cohorts are large enough to distinguish CIN3(+) risks among women with minor abnormalities versus negative cytology because of low incidence. The New Mexico Human Papillomavirus (HPV) Pap Registry offers a unique opportunity to evaluate cervical cancer screening in a diverse population across a broad-spectrum of health service delivery.

METHODS

Kaplan-Meier and logistic-Weibull survival models were used to estimate cumulative risks of CIN3(+) among women ages 21 to 64 who were screened in New Mexico between 2007 and 2011 with negative, equivocal or mildly abnormal cytology, that is, atypical squamous cells of undetermined significance (ASC-US; with or without HPV triage), or low-grade squamous intraepithelial lesions (LSIL).

RESULTS

We identified 452,045 women meeting the selection criteria. The 3-year CIN3(+) risks for women with negative, ASC-US, and LSIL cytology were 0.30%, 2.6%, and 5.2%, respectively. HPV triage of ASC-US stratified 3-year CIN3(+) risks were 0.72% for HPV-negative and 7.7% for HPV-positive. Risks tended to decline after age 30 for all screening results.

CONCLUSIONS

In this state-wide population-based cohort, cytology and HPV triage of ASC-US stratified women's CIN3(+) risk into similar patterns observed previously, suggesting the validity of screening guidelines for diverse populations in the United States. Absolute risk estimates should be compared across other large populations.

IMPACT

Strategies for HPV triage of ASC-US derived from clinical trials are upheld in large clinical practice settings and across diverse screening populations in the United States.

Authors+Show Affiliations

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland.Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland.Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland.Information Management Services Inc., Calverton, Maryland.Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, United Kingdom.Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.Albert Einstein College of Medicine, New York, New York.Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. cwheeler@salud.unm.edu.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

26518316

Citation

Gage, Julia C., et al. "Risk Stratification Using Human Papillomavirus Testing Among Women With Equivocally Abnormal Cytology: Results From a State-Wide Surveillance Program." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 25, no. 1, 2016, pp. 36-42.
Gage JC, Hunt WC, Schiffman M, et al. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiol Biomarkers Prev. 2016;25(1):36-42.
Gage, J. C., Hunt, W. C., Schiffman, M., Katki, H. A., Cheung, L. C., Cuzick, J., ... Wheeler, C. M. (2016). Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 25(1), pp. 36-42. doi:10.1158/1055-9965.EPI-15-0669.
Gage JC, et al. Risk Stratification Using Human Papillomavirus Testing Among Women With Equivocally Abnormal Cytology: Results From a State-Wide Surveillance Program. Cancer Epidemiol Biomarkers Prev. 2016;25(1):36-42. PubMed PMID: 26518316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. AU - Gage,Julia C, AU - Hunt,William C, AU - Schiffman,Mark, AU - Katki,Hormuzd A, AU - Cheung,Li C, AU - Cuzick,Jack, AU - Myers,Orrin, AU - Castle,Philip E, AU - Wheeler,Cosette M, AU - ,, Y1 - 2015/10/30/ PY - 2015/06/22/received PY - 2015/09/23/accepted PY - 2015/11/1/entrez PY - 2015/11/1/pubmed PY - 2016/10/26/medline SP - 36 EP - 42 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 25 IS - 1 N2 - BACKGROUND: Clinical guidelines for cervical cancer screening have incorporated comparative risks of cervical intraepithelial neoplasia grade 3 or cancer (CIN3(+)) for various screening outcomes to determine management. Few cohorts are large enough to distinguish CIN3(+) risks among women with minor abnormalities versus negative cytology because of low incidence. The New Mexico Human Papillomavirus (HPV) Pap Registry offers a unique opportunity to evaluate cervical cancer screening in a diverse population across a broad-spectrum of health service delivery. METHODS: Kaplan-Meier and logistic-Weibull survival models were used to estimate cumulative risks of CIN3(+) among women ages 21 to 64 who were screened in New Mexico between 2007 and 2011 with negative, equivocal or mildly abnormal cytology, that is, atypical squamous cells of undetermined significance (ASC-US; with or without HPV triage), or low-grade squamous intraepithelial lesions (LSIL). RESULTS: We identified 452,045 women meeting the selection criteria. The 3-year CIN3(+) risks for women with negative, ASC-US, and LSIL cytology were 0.30%, 2.6%, and 5.2%, respectively. HPV triage of ASC-US stratified 3-year CIN3(+) risks were 0.72% for HPV-negative and 7.7% for HPV-positive. Risks tended to decline after age 30 for all screening results. CONCLUSIONS: In this state-wide population-based cohort, cytology and HPV triage of ASC-US stratified women's CIN3(+) risk into similar patterns observed previously, suggesting the validity of screening guidelines for diverse populations in the United States. Absolute risk estimates should be compared across other large populations. IMPACT: Strategies for HPV triage of ASC-US derived from clinical trials are upheld in large clinical practice settings and across diverse screening populations in the United States. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/26518316/Risk_Stratification_Using_Human_Papillomavirus_Testing_among_Women_with_Equivocally_Abnormal_Cytology:_Results_from_a_State_Wide_Surveillance_Program_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=26518316 DB - PRIME DP - Unbound Medicine ER -